Its cancer‐promoting phenotype needs to be verified through in vitro experiments (such as inhibition of tumor cell proliferation/migration after knocking down GABRP) and in vivo models (delayed growth of mouse transplanted tumors) to clarify the biological basis of clinical association. This evidence concerns the gene GABRP and neoplasm.